Boston Therapeutics, Inc. focuses on the discovery, production, and... Boston Therapeutics, Inc. focuses on the discovery, production, and commercialization of therapeutic drugs aimed at fulfilling critical unmet medical needs in the areas of diabetes and inflammatory diseases. The company's pipeline features BTI-320, a non-systemic, carbohydrate-based tablet currently in Phase II clinical trials, which is being developed to reduce post-meal blood glucose levels in patients with pre-diabetes and type 2 diabetes. They also have IPOXYN, an injectable medication designed to prevent tissue necrosis and address conditions caused by low oxygen, such as diabetic foot ulcers and other related vascular or neurological complications. Additionally, Boston Therapeutics is progressing with BTI-410, a peptide injectable compound also in Phase II clinical development, intended to stimulate beta cell maturation in the pancreas. This could potentially serve as a new insulin-producing cell agent for individuals with type 2 diabetes and type 1 patients on immunosuppression therapy following a kidney transplant. Complementing its pharmaceutical endeavors, the company offers SUGARDOWN, a non-systemic, polysaccharide-based dietary supplement designed to support healthy blood glucose management, and OXYFEX, a veterinary application that acts as an oxygen delivery agent, similar to a red blood cell replacement, for treating ischemia, trauma, and blood loss during surgical procedures. The firm further extends its offerings to include Automatic Retinal Image Analysis (ARIA), a diagnostic tool used for screening cardiovascular risks, including stroke. Boston Therapeutics, Inc. maintains its headquarters in Lawrence, Massachusetts.
